- Research Article
72
- 10.1016/j.ijpharm.2009.09.043
Oxybutynin permeation in skin: The influence of drug and solvent activity
- Sep 30, 2009
- International Journal of Pharmaceutics
- P Santos + 3 more +3
Publications from 2021 to 2026
Showing 5 of 5 papers
Oxybutynin permeation in skin: The influence of drug and solvent activity
An initial pharmacokinetic study with a Metered Dose Transdermal System® for delivery of the progestogen Nestorone® as a possible future contraceptive
Systemic Delivery of Drugs to Humans via Inhalation
Unwanted systemic absorption of drugs delivered for the local treatment of respiratory disease is well documented. Methods to minimize this now exist, especially for reduction of oropharyngeal deposition. While small molecules appear to be absorbed also from the airways, it is the alveolated regions that provide a large absorptive surface. Lung has been used as a portal for systemic delivery of substances such as anesthetics, nicotine and a number of illicit drugs. Much research has lead to the solutions of the fundamental technical hurdles of practicable delivery of systemic therapeutic drugs in milligram quantities to the lung efficiently and reproducibly. Commercial manufacturing processes exist for production of delivery systems suitable for this purpose. Generally, the deposition of small molecules in the "deep lung" leads to high absorption rates, making the inhalation delivery attractive for drugs with intended rapid onset of action. Many therapeutics, especially peptides and proteins, that cannot be delivered systemically non-invasively, are absorbed with various degrees of systemic bioavailability via inhalation. The critical factor for efficient and reproducible systemic delivery is lung deposition which depends on the properties of drug particles (size, shape, density, hygroscopicity, velocity, charge) and the state of the respiratory system (including the individual's anatomy, age, sex, disease, lung volume). While concerns exist about the potential adverse reactions of the immune system to therapeutic proteins and peptides delivered to and through the lung, there is not much data on the immune response or its link to any safety issues with inhaled biologics. Desirable systemic immune effects have been demonstrated by cytokine delivery to the lung.
Read moreSynergistic enhancement of testosterone transdermal delivery
Effect of Mouthpiece Washing on Aerosol Performance of CFC‐Free Ventolin™
The prescribing information for chlorofluorocarbon (CFC)‐free salbutamol metered‐dose inhalers carries a strongly‐worded instruction to wash the mouthpiece weekly, but patients rarely carry this out. This study investigated the effect of washing/not washing the mouthpiece on CFC‐free Ventolin™ aerosol performance. Twelve CFC‐free Ventolin™ inhalers were actuated two puffs four times/day, and assessed by unit dose sampler and cascade impactor on Days 1, 7, 8, 14, 15, 21, and 22 (“through‐life,” i.e., over the entire content of the inhaler). The mouthpieces of six inhalers were washed after the last actuation on Days 7, 14, and 21. A single priming maneuver, as recommended by the manufacturer, was sufficient for fine particle mass. There were no significant through‐life differences in delivered dose between washed and unwashed inhalers. Without washing, fine particle mass fell from 47 µg to 33 µg (Friedman p = 0.002). Fine particle mass increased significantly after washing (median change + 11.2 µg, p = 0.019 cf. unwashed). Large particle mass showed no significant through‐life trend for washed or unwashed inhalers, but was significantly reduced after washing (p = 0.04 cf. unwashed). This study shows a progressive through‐life reduction in fine particle mass from CFC‐free Ventolin™ inhalers, which is prevented by weekly mouthpiece washing. However, in view of the steep bronchodilator dose‐response curve for salbutamol, further studies are needed to determine whether such device care is clinically necessary.
Read more